1059 related articles for article (PubMed ID: 15308995)
1. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Bhatt DL; Topol EJ;
Am Heart J; 2004 Aug; 148(2):263-8. PubMed ID: 15308995
[TBL] [Abstract][Full Text] [Related]
2. Combination antiplatelet agents for secondary prevention of ischemic stroke.
Vande Griend JP; Saseen JJ
Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
[TBL] [Abstract][Full Text] [Related]
3. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.
Bhatt DL; Flather MD; Hacke W; Berger PB; Black HR; Boden WE; Cacoub P; Cohen EA; Creager MA; Easton JD; Hamm CW; Hankey GJ; Johnston SC; Mak KH; Mas JL; Montalescot G; Pearson TA; Steg PG; Steinhubl SR; Weber MA; Fabry-Ribaudo L; Hu T; Topol EJ; Fox KA;
J Am Coll Cardiol; 2007 May; 49(19):1982-8. PubMed ID: 17498584
[TBL] [Abstract][Full Text] [Related]
4. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Berger PB; Bhatt DL; Fuster V; Steg PG; Fox KA; Shao M; Brennan DM; Hacke W; Montalescot G; Steinhubl SR; Topol EJ;
Circulation; 2010 Jun; 121(23):2575-83. PubMed ID: 20516378
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial).
Dasgupta A; Steinhubl SR; Bhatt DL; Berger PB; Shao M; Mak KH; Fox KA; Montalescot G; Weber MA; Haffner SM; Dimas AP; Steg PG; Topol EJ;
Am J Cardiol; 2009 May; 103(10):1359-63. PubMed ID: 19427428
[TBL] [Abstract][Full Text] [Related]
6. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease.
Mehta SR; Yusuf S;
Eur Heart J; 2000 Dec; 21(24):2033-41. PubMed ID: 11102254
[TBL] [Abstract][Full Text] [Related]
7. Evolving perspectives on clopidogrel in the treatment of ischemic stroke.
Gorelick P; Sechenova O; Hennekens CH
J Cardiovasc Pharmacol Ther; 2006 Dec; 11(4):245-8. PubMed ID: 17220470
[TBL] [Abstract][Full Text] [Related]
8. MATCH results: implications for the internist.
Lutsep HL
Am J Med; 2006 Jun; 119(6):526.e1-7. PubMed ID: 16750967
[TBL] [Abstract][Full Text] [Related]
9. Identification of and management approaches for the high-risk patient.
Bhatt DL
Am J Cardiol; 2006 Dec; 98(12A):22Q-29Q. PubMed ID: 17169626
[TBL] [Abstract][Full Text] [Related]
10. Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data.
Diener HC; Bogousslavsky J; Brass LM; Cimminiello C; Csiba L; Kaste M; Leys D; Matias-Guiu J; Rupprecht HJ
Cerebrovasc Dis; 2004; 17(2-3):253-61. PubMed ID: 14981346
[TBL] [Abstract][Full Text] [Related]
11. Results of the management of atherothrombosis with clopidogrel in high-risk patients trial: implications for the neurologist.
Fisher M
Arch Neurol; 2006 Jan; 63(1):20-4. PubMed ID: 16401733
[TBL] [Abstract][Full Text] [Related]
12. Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial.
Hart RG; Bhatt DL; Hacke W; Fox KA; Hankey GJ; Berger PB; Hu T; Topol EJ;
Cerebrovasc Dis; 2008; 25(4):344-7. PubMed ID: 18303254
[TBL] [Abstract][Full Text] [Related]
13. Aspirin resistance or variable response or both?
Cheng X; Chen WH; Simon DI
Am J Cardiol; 2006 Nov; 98(10A):11N-17N. PubMed ID: 17097412
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E;
Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826
[TBL] [Abstract][Full Text] [Related]
15. A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Bhatt DL; Fox KA; Hacke W; Berger PB; Black HR; Boden WE; Cacoub P; Cohen EA; Creager MA; Easton JD; Flather MD; Haffner SM; Hamm CW; Hankey GJ; Johnston SC; Mak KH; Mas JL; Montalescot G; Pearson TA; Steg PG; Steinhubl SR; Weber MA; Booth J; Topol EJ;
Am Heart J; 2005 Sep; 150(3):401. PubMed ID: 16169314
[TBL] [Abstract][Full Text] [Related]
16. Update on aspirin in the treatment and prevention of cardiovascular disease.
Hennekens CH
Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
[TBL] [Abstract][Full Text] [Related]
17. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
; Alexander JH; Becker RC; Bhatt DL; Cools F; Crea F; Dellborg M; Fox KA; Goodman SG; Harrington RA; Huber K; Husted S; Lewis BS; Lopez-Sendon J; Mohan P; Montalescot G; Ruda M; Ruzyllo W; Verheugt F; Wallentin L
Circulation; 2009 Jun; 119(22):2877-85. PubMed ID: 19470889
[TBL] [Abstract][Full Text] [Related]
18. Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].
Kirshner HS
Int J Clin Pract; 2007 Oct; 61(10):1739-48. PubMed ID: 17877660
[TBL] [Abstract][Full Text] [Related]
19. Antiplatelet drugs in secondary prevention after acute myocardial infarction.
Thizon-de-Gaulle I
Rev Port Cardiol; 1998 Dec; 17(12):993-7. PubMed ID: 9973860
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of clopidogrel plus aspirin for secondary prevention of cardiovascular events in Canada for patients with established cardiovascular disease: Results from the CHARISMA trial.
Chen J; Shi C; Mahoney EM; Dunn ES; Rinfret S; Caro JJ; O'Brien J; El-Hadi W; Bhatt DL; Topol EJ; Cohen DJ
Can J Cardiol; 2011; 27(2):222-31. PubMed ID: 21459271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
